1 |
Chim L, Kelly PJ, Salkeld G, et al (2010). Are cancer drugs less likely to be recommended for listing by the pharmaceutical benefits advisory committee in Australia? Pharmacoeconomics, 28, 463-75.
DOI
ScienceOn
|
2 |
Daniels N, Sabin J (1997). Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. Philos Public Aff, 26, 303-50.
DOI
ScienceOn
|
3 |
Daniels N, Teagarden JR, Sabin JE (2003). An ethical template for pharmacy benefits. Health Affairs, 22, 125-37.
DOI
|
4 |
DeJean D, Giacomini M, Schwartz L, et al (2009). Ethics in Canadian health technology assessment: a descriptive review. Int J Technol Assess Health Care, 25, 463-9.
DOI
ScienceOn
|
5 |
Droste S, Dintsios CM, Gerber A (2010). Information on ethical issues in health technology assessment: how and where to find them. Int J Technol Assess Health Care, 26, 441-9.
DOI
ScienceOn
|
6 |
Drummond M, Evans B, LeLorier J, et al (2009). Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology. Can J Clin Pharmacol, 16, 273-81.
|
7 |
Drummond MF, Schwartz JS, Jonsson B, et al (2008). Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care, 24, 244-58.
|
8 |
Abelson J, Giacomini M, Lehoux P, et al (2007). Bringing 'the public' into health technology assessment and coverage policy decisions: from principles to practice. Health Policy, 82, 37-50.
DOI
ScienceOn
|
9 |
Burls A, Caron L, Cleret de Langavant G, et al (2011). Tackling ethical issues in health technology assessment: a proposed framework. Int J Technol Assess Health Care, 27, 230-7.
DOI
ScienceOn
|
10 |
Hauck K, Tsuchiya A (2011). Health dynamics: implications for efficiency and equity in priority setting. Value Health, 14, 387-9.
DOI
ScienceOn
|
11 |
Health Insurance Review and Assessment Service (HIRA) (2007). Guidelines and Scope for Economic Evaluation of Pharmaceuticals for Formulary Listing in Korea. Seoul.
|
12 |
Hofmann BM (2008). Why ethics should be part of health technology assessment. Int J Technol Assess Health Care, 24, 423-9.
|
13 |
Kamae I (2010). Value-based approaches to healthcare systems and pharmacoeconomics requirements in Asia: South Korea, Taiwan, Thailand and Japan. Pharmacoeconomics, 28, 831-8.
DOI
ScienceOn
|
14 |
Kwon S (2009). Pharmaceutical Policy in South Korea. In:Prescribing cultures and pharmaceutical policy in the Asia-Pacific. Eggleston K, ed. Stanford: The Walter H. Shorenstein Asia-Pacific Research Center, 444.
|
15 |
Low E (2007). Many new cancer drugs in the United Kingdom are facing negative NICE rulings. J Clin Oncol, 25, 2635-6.
DOI
ScienceOn
|
16 |
McKie J, Richardson J (2003). The rule of rescue. Soc Sci Med, 56, 2407-19.
DOI
ScienceOn
|
17 |
Oortwijn W, Mathijssen J, Banta D (2010). The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries. Health Policy, 95, 174-84.
DOI
ScienceOn
|
18 |
Pinkerton S (2002). Ethical issues in cost-effectiveness analysis. Evaluation and Program Planning, 25, 71-83.
DOI
ScienceOn
|
19 |
Rawlins MD, Culyer AJ (2004). National Institute for Clinical Excellence and its value judgments. BMJ, 329, 224-7.
DOI
ScienceOn
|
20 |
Rocchi A, Menon D, Verma S, et al (2008). The role of economic evidence in Canadian oncology reimbursement decisionmaking: to lambda and beyond. Value Health, 11, 771-83.
DOI
ScienceOn
|
21 |
Schlander M, Beck M (2009). Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin, 25, 1285-93.
DOI
|
22 |
Schnipper LE, Meropol NJ, Brock DW (2010). Value and cancer care: toward an equitable future. Clin Cancer Res, 16, 6004-8.
DOI
ScienceOn
|
23 |
Yang BM (2009). The future of health technology assessment in healthcare decision making in Asia. Pharmacoeconomics, 27, 891-901.
DOI
ScienceOn
|
24 |
Weinstein MC (1988). A QALY is a QALY--or is it? J Health Econ, 7, 289-90.
DOI
ScienceOn
|